These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28800598)

  • 21. Recurrence of dual-strain Clostridium difficile infection in an in vitro human gut model.
    Crowther GS; Chilton CH; Todhunter SL; Nicholson S; Freeman J; Wilcox MH
    J Antimicrob Chemother; 2015 Aug; 70(8):2316-21. PubMed ID: 25925596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genomic and phenotypic diversity of Clostridium difficile during long-term sequential recurrences of infection.
    Sachsenheimer FE; Yang I; Zimmermann O; Wrede C; Müller LV; Gunka K; Groß U; Suerbaum S
    Int J Med Microbiol; 2018 Apr; 308(3):364-377. PubMed ID: 29490877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new strategy for the prevention of Clostridium difficile infection.
    Howerton A; Patra M; Abel-Santos E
    J Infect Dis; 2013 May; 207(10):1498-504. PubMed ID: 23420906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sporulation properties and antimicrobial susceptibility in endemic and rare Clostridium difficile PCR ribotypes.
    Zidaric V; Rupnik M
    Anaerobe; 2016 Jun; 39():183-8. PubMed ID: 27095618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Fidaxomicin with C. difficile Spores: Effects of Persistence on Subsequent Spore Recovery, Outgrowth and Toxin Production.
    Chilton CH; Crowther GS; Ashwin H; Longshaw CM; Wilcox MH
    PLoS One; 2016; 11(8):e0161200. PubMed ID: 27556739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model.
    Chilton CH; Freeman J; Crowther GS; Todhunter SL; Wilcox MH
    J Antimicrob Chemother; 2012 Oct; 67(10):2434-7. PubMed ID: 22723601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Time-kill kinetics of cadazolid and comparator antibacterial agents against different ribotypes of Clostridium difficile.
    Skinner K; Birchall S; Corbett D; Thommes P; Locher HH
    J Med Microbiol; 2018 Sep; 67(9):1402-1409. PubMed ID: 30052178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of the effect of oritavancin on Clostridium difficile spore germination, outgrowth and recovery.
    Chilton CH; Freeman J; Baines SD; Crowther GS; Nicholson S; Wilcox MH
    J Antimicrob Chemother; 2013 Sep; 68(9):2078-82. PubMed ID: 23759507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Whole-genome sequencing improves discrimination of relapse from reinfection and identifies transmission events among patients with recurrent Clostridium difficile infections.
    Mac Aogáin M; Moloney G; Kilkenny S; Kelleher M; Kelleghan M; Boyle B; Rogers TR
    J Hosp Infect; 2015 Jun; 90(2):108-16. PubMed ID: 25935700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors for recurrence in patients with Clostridium difficile infection due to 027 and non-027 ribotypes.
    Falcone M; Tiseo G; Iraci F; Raponi G; Goldoni P; Delle Rose D; Santino I; Carfagna P; Murri R; Fantoni M; Fontana C; Sanguinetti M; Farcomeni A; Antonelli G; Aceti A; Mastroianni C; Andreoni M; Cauda R; Petrosillo N; Venditti M
    Clin Microbiol Infect; 2019 Apr; 25(4):474-480. PubMed ID: 29964230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Clostridium difficile isolates from individuals with recurrent and single episode of infection.
    Richardson C; Kim P; Lee C; Bersenas A; Weese JS
    Anaerobe; 2015 Jun; 33():105-8. PubMed ID: 25769665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection.
    Gerding DN; Hecht DW; Louie T; Nord CE; Talbot GH; Cornely OA; Buitrago M; Best E; Sambol S; Osmolski JR; Kracker H; Locher HH; Charef P; Wilcox M
    J Antimicrob Chemother; 2016 Jan; 71(1):213-9. PubMed ID: 26433782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A combination of the probiotic and prebiotic product can prevent the germination of Clostridium difficile spores and infection.
    Rätsep M; Kõljalg S; Sepp E; Smidt I; Truusalu K; Songisepp E; Stsepetova J; Naaber P; Mikelsaar RH; Mikelsaar M
    Anaerobe; 2017 Oct; 47():94-103. PubMed ID: 28465256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibacterial activity of rhodomyrtone on Clostridium difficile vegetative cells and spores in vitro.
    Srisuwan S; Mackin KE; Hocking D; Lyras D; Bennett-Wood V; Voravuthikunchai SP; Robins-Browne RM
    Int J Antimicrob Agents; 2018 Nov; 52(5):724-729. PubMed ID: 30145248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First clinical and microbiological characterization of Clostridium difficile infection in a Croatian University Hospital.
    Novak A; Spigaglia P; Barbanti F; Goic-Barisic I; Tonkic M
    Anaerobe; 2014 Dec; 30():18-23. PubMed ID: 25079669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The ClosER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes, 2011-2014.
    Freeman J; Vernon J; Pilling S; Morris K; Nicholson S; Shearman S; Longshaw C; Wilcox MH;
    Clin Microbiol Infect; 2018 Jul; 24(7):724-731. PubMed ID: 29066403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical features and characteristics of Clostridium difficile PCR-ribotype 176 infection: results from a 1-year university hospital internal ward study.
    Drabek J; Nyc O; Krutova M; Stovicek J; Matejkova J; Keil R
    Ann Clin Microbiol Antimicrob; 2015 Dec; 14():55. PubMed ID: 26698842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model.
    Ochsner UA; Bell SJ; O'Leary AL; Hoang T; Stone KC; Young CL; Critchley IA; Janjic N
    J Antimicrob Chemother; 2009 May; 63(5):964-71. PubMed ID: 19251726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clostridium difficile infection among immunocompromised patients in Rio de Janeiro, Brazil and detection of moxifloxacin resistance in a ribotype 014 strain.
    Secco DA; Balassiano IT; Boente RF; Miranda KR; Brazier J; Hall V; dos Santos-Filho J; Lobo LA; Nouér SA; Domingues RM
    Anaerobe; 2014 Aug; 28():85-9. PubMed ID: 24907488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Co-amoxiclav induces proliferation and cytotoxin production of Clostridium difficile ribotype 027 in a human gut model.
    Chilton CH; Freeman J; Crowther GS; Todhunter SL; Nicholson S; Wilcox MH
    J Antimicrob Chemother; 2012 Apr; 67(4):951-4. PubMed ID: 22279183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.